These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36301892)

  • 21. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed Combination for the Treatment of Dyslipidaemia.
    Ferri N; Ruscica M; Santos RD; Corsini A
    Curr Atheroscler Rep; 2023 Oct; 25(10):691-699. PubMed ID: 37715044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
    Doggrell SA
    Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bempedoic Acid: How Will It Shape the Future Lipid-Lowering Landscape? Mode of Action, Evidence, and Clinical Use.
    Drexel H; Mader A
    Cardiology; 2024; 149(1):71-77. PubMed ID: 37989119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors.
    Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C
    J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
    Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bempedoic acid: Review of a novel therapy in lipid management.
    Delevry D; Gupta EK
    Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Bempedoic Acid in Dyslipidemia Management.
    Kelly MS; Sulaica EM; Beavers CJ
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
    McKinley EC; Bittner VA; Brown TM; Chen L; Exter J; Farkouh ME; Huang L; Jackson EA; Levitan EB; Orroth KK; Reading SR; Rosenson RS; Safford MM; Woodward M; Muntner P; Colantonio LD
    Cardiovasc Drugs Ther; 2023 Feb; 37(1):107-116. PubMed ID: 34599698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying Patients for Nonstatin Therapy.
    Robinson JG; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and future options in cholesterol lowering treatments.
    Elis A
    Eur J Intern Med; 2023 Jun; 112():1-5. PubMed ID: 36813611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.